Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Myovant Sciences Shares Rise on NDA Filing for Uterine Fibroid Combination Therapy Drug

Shares of Myovant Sciences traded 40% higher after the company reported that it has submitted a New Drug Application to the FDA for once-daily relugolix combination tablet for the treatment of women with uterine fibroids. Healthcare company Myovant Sciences Ltd. (...
Streetwise Reports | June 2, 2020 |

Neovasc Shares Climb 80% Upon FDA Premarket Approval Filing for Refractory Angina Device

Shares of specialty cardiovascular medical device company Neovasc Inc. opened more than 100% higher after the firm reported that it submitted a Premarket Approval application to the FDA for its Neovasc Reducer device for use in the treatment of refractory angina. This...
Streetwise Reports | January 3, 2020 |

Transenterix Shares Trade Up 25% on FDA Filing for First Machine Vision System in Robotic Surgery

Shares of Transenterix opened 50% higher after the company reported that it has submitted a 510(k) submission to the FDA for the first machine vision system for use in robotic surgery. This morning, medical device company TransEnterix Inc. (TRXC:NYSE.American) , whic...
Streetwise Reports | January 15, 2020 |

Klondike Golden Moments

Foreword: This tale grew from a chance nugget discovery along the shore of a humble Yukon creek carving through the remote Territory and became the great history of the Klondike Gold Rush. Join author James Kwantes as he touches down in the Yukon with 12 exciting stories and c...
James Kwantes | August 15, 2019 |

F Disrespectful Fiduciary Responsibility

Concerned under the existential dread that "The robots could take over" and take control of the job of writer as easily as they did to that of the cashier or comedian, I attempted to create an article via an AI algoritm, the result .... There has been a lot of talk in the...
According to published reports | May 6, 2021 |

Better Prospects for Gold in 2020?

Will 2020 be better than 2019 for the yellow metal? We invite you to read our today’s article, which provides an important update of the macroeconomic outlook for 2020 we painted one month ago. Read it and learn what has changed among the fundamental factors an...
Arkadiusz Sieron | February 7, 2020 |

Artificial Intelligence Fibonacci Trading System Predicts Next Price Move

Now that you’ve learned about Fibonacci Price Theory Part I and how major and minor Fibonacci Price Pivots help to map out true price structure Part II , we’ll continue our research article illustrating why we believe a deeper price...
Chris Vermeulen | April 13, 2020 |

FDA Accepts NDA for Global Blood Therapeutics' Sickle Cell Drug; Shares Up 14%

Shares of Global Blood Therapeutics are trading more than 14% higher after the FDA accepted its New Drug Application filing for Voxelotor, a drug used in the treatment of sickle cell disease. Earlier today clinical-stage biopharmaceutical firm Global Blood Therapeuti...
Streetwise Reports | September 6, 2019 |

Analyst: G1 Minimizes the Carnage of Chemotherapy

ROTH Capital Partners initiates coverage on U.S. oncology biopharma G1 Therapeutics that is now filing an NDA. In a June 26 research note, analyst Tony Butler reported that ROTH Capital Partners initiated coverage on G1 Therapeutics Inc. (GTHX:NASDAQ) with a Buy ...
Streetwise Reports | July 2, 2020 |

Hemostemix Founder: A Man with a Compassionate Heart

The Canadian stem cell company Hemostemix Inc. ( TSX-V: HEM , OTC: HMTXF ) was founded by a man who truly had a compassionate heart and a clear intent to establish a breakthrough in heart disease using the same technology that saved his life. Roger Bergersen, who train...
Featured Submission | December 14, 2020 |
1 2 3 4 5 6 7